Tag Archives: biotech companies

Guest Post: Do Small Biopharma Firms Really Face Disproportionate Risk from Securities Class Actions?

It is now a commonplace observation in the D&O arena that life sciences companies – and in particular small biopharma companies – are frequent targets of securities class action lawsuits. As a result of these observations about claims frequency, biopharma companies often pay more than other kinds of companies for their D&O insurance. But do … Continue Reading

Biotech Companies Sued Frequently But Do They Really Represent a Heightened Risk Class?

As has been documented on this blog and elsewhere, life sciences companies in general, and developmental stage biotechnology companies in particular, are frequent securities class action litigation targets. But does that really justify the perception of early stage biotech companies as representing a heightened securities litigation risk class for D&O insurers? A recent law firm … Continue Reading
LexBlog